This article provides a summary of a previously published paper: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. The paper reported the results of the CHAMPION-MG trial which investigated the drug ravulizumab in the rare disease, myasthenia gravis. Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis (MP4 594600 KB).
No takes yet. Share an insight, caveat, or question.
Vu et al. (2023) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: